Kyverna Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2023 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Kyverna Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2023 to Q4 2024.
  • Kyverna Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$37.5M, a 81.4% decline year-over-year.
  • Kyverna Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$127M, a 111% decline year-over-year.
  • Kyverna Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$127M, a 111% decline from 2023.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$127M -$37.5M -$16.8M -81.4% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-27
Q3 2024 -$111M -$34.5M -$19M -123% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$91.6M -$28.8M -$15.7M -120% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-13
Q1 2024 -$75.9M -$26.7M -$15.6M -140% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-13
Q4 2023 -$60.4M -$20.7M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-27
Q3 2023 -$15.5M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$13.1M Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-13
Q1 2023 -$11.1M Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.